{
  "docId": "019de075-7d9e-72c3-b72b-f46b67767727",
  "docSlug": "53c1bfc711678d7524a7d4316a5473e9",
  "documentTitle": "Chimerix | Investor Presentation Deck | 43 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 43,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 11,
  "notes": "The chart illustrates dose levels 1-11 with checkmarks indicating completed levels and a clear distinction between weekly and 3-day dosing regimens.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-7d9e-72c3-b72b-f46b67767727/35",
  "deckHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727",
  "deckJsonHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727.json",
  "deckAnchorHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.495,
        "w": 0.515,
        "x": 0.338,
        "y": 0.215
      },
      "kind": "chart",
      "text": "Dose escalation chart showing weekly vs 3-day dosing levels",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1260b7b4-9d0b-47b4-90af-b921c59ffb3d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.28,
        "x": 0.016,
        "y": 0.23
      },
      "kind": "list",
      "text": "No DLTs observed with weekly dosing; Similar safety profile in adults and pediatrics; Majority of treatment-related AEs are mild to moderate; Most common treatment-related events are fatigue, lymphocyte count decreased, and vomiting; No dose related toxicity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec9ca539-a6d5-4740-840b-d6759b78c2c0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.824,
        "x": 0.088,
        "y": 0.87
      },
      "kind": "paragraph",
      "text": "In vitro data indicates correlation between exposure time and tumor cell viability; more frequent dosing schedule designed to increase duration of target exposure",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ffce2357-6fc7-46b3-bd3b-02bc589bd06a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.26,
        "x": 0.102,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Dose level 6 was conducted in adults only; 2. Pediatric dose scaled by body weight",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "defd3bf5-c48a-40c4-a336-add3c130ea5d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.334,
        "x": 0.333,
        "y": 0.121
      },
      "kind": "title",
      "text": "Dose escalation on track for completion in 1H24",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "998523f7-3ad9-43c5-91d2-fd01d4023dbf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.704,
        "x": 0.148,
        "y": 0.068
      },
      "kind": "title",
      "text": "ONC206 dose escalation increasing to more frequent dosing",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2227968c-7dc4-4c05-b583-6ad1b2c856d7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 43,
      "from": 16,
      "beatId": "159a3ef0-298f-499a-afc1-676405bbdbe9",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The deck presents ONC201 as a solution, including its mechanism of action, market opportunity, and development plans",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 43,
      "from": 16,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "cb576a48-1f93-4d7c-8d9b-075787961712",
      "evidence": "The deck presents ONC201's potential for efficacy and market opportunity",
      "position": 1,
      "objective": "Can ONC201 be a quick win and a big bet for Chimerix?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}